Administering oral medications through enteral feeding tubes presents unique challenges for pharmaceutical developers, particularly as regulatory expectations continue to evolve globally.
In a recent article published in International Pharmaceutical Industry (IPI), Quotient Sciences experts Nazim and Justin explore how regulatory agencies are addressing this increasingly important aspect of drug development.
The article examines current guidance from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), highlighting key considerations for assessing the suitability of oral drug products for administration via enteral feeding tubes. As patient populations become more diverse and accessible medication delivery remains a critical focus, understanding these regulatory perspectives is becoming essential for sponsors developing oral dosage forms.
Emphasis on patient-centric drug development
Nazim and Justin discuss the growing emphasis on patient-centric drug development, the challenges associated with generating administration data, and the importance of aligning development strategies with regulatory expectations across regions. They offer valuable context for pharmaceutical and biotech organizations looking to support broader patient access while reducing regulatory risk.
For companies navigating formulation development, clinical programs, or regulatory submissions, staying informed on these emerging requirements can help streamline development, while looking at how to improve patient outcomes. Read the full article on the International Pharmaceutical Industry website.
For more on this topic: Meet our team at EuPFI 2026
Quotient Sciences will be attending and presenting as part of the EuPFI 2026 conference about this topic. See event details or contact us for more information or to schedule a meeting at the event.